Stock Events

Stock Events

NewcelX

$3.38

55

+$0.13+4% Thursday 20:00

-$0.12-3.55%Thursday 20:10After hours

Statistics

Day High

3.34

Day Low

3.34

52W High

24.6

52W Low

1.83

Volume

-

Avg. Volume

-

Mkt Cap

19.52M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

2SepExpected

Q1 2024

Q3 2025

Q4 2025

Q2 2026

-84

-56.18

-28.35

-0.53

Expected EPS

-0.53

Actual EPS

-0.53

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NCEL. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Jazz Pharmaceuticals

Jazz Pharmaceuticals competes directly with NLS Pharmaceutics in the narcolepsy treatment market, offering Xyrem and Xywav, leading treatments for cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients.

Takeda Pharmaceutical

Takeda Pharmaceutical Company offers Wakix (pitolisant), which competes in the narcolepsy treatment market, particularly targeting excessive daytime sleepiness, a key area for NLS Pharmaceutics.

Heron Therapeutics

Heron Therapeutics, with its focus on CNS disorders including treatments for postoperative pain, indirectly competes with NLS Pharmaceutics by targeting overlapping areas in the central nervous system disorder treatment market.

Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries offers several CNS disorder treatments, including generic versions of modafinil and armodafinil for narcolepsy, directly competing with NLS Pharmaceutics' focus on narcolepsy and sleep disorders.

Biogen competes in the broader CNS disorder space, including multiple sclerosis and Alzheimer's, which overlaps with NLS Pharmaceutics' focus on central nervous system disorders, albeit in different therapeutic areas.

Acadia Pharmaceuticals

ACADIA Pharmaceuticals, with its focus on CNS disorders such as Parkinson’s disease psychosis, competes in the broader market for neurological treatments, indirectly competing with NLS Pharmaceutics.

Alkermes competes in the CNS therapeutic area with treatments for schizophrenia, bipolar I disorder, and depression, indirectly competing with NLS Pharmaceutics by targeting the broader CNS disorder market.

Neurocrine Biosciences

Neurocrine Biosciences focuses on neurological and endocrine diseases, including treatments for tardive dyskinesia and Parkinson’s disease, placing it in indirect competition with NLS Pharmaceutics in the CNS disorder space.

About

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Show more...

CEO

Ronen Twito

Employees

4

Country

Switzerland

ISIN

CH1442297896

Listings

0 Comments

Share your thoughts

FAQ

What is NewcelX stock price today?▼

The current price of NCEL is $3.38 USD — it has increased by +4% in the past 24 hours. Watch NewcelX stock price performance more closely on the chart.

What is NewcelX stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange NewcelX stocks are traded under the ticker NCEL.

What is NewcelX market cap?▼

Today NewcelX has the market capitalization of 19.52M

When is the next NewcelX earnings date?▼

NewcelX is going to release the next earnings report on March 03, 2027.

What were NewcelX earnings last quarter?▼

NCEL earnings for the last quarter are -0.53 USD per share, whereas the estimation was -0.53 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.

How many employees does NewcelX have?▼

As of September 11, 2026, the company has 4 employees.

In which sector is NewcelX located?▼

NewcelX operates in the Health & Wellness sector.

When did NewcelX complete a stock split?▼

The last stock split for NewcelX was on October 31, 2025 with a ratio of 1:10.

Where is NewcelX headquartered?▼

NewcelX is headquartered in Kloten, Switzerland.